Michael Gross, MD
Rheumatology · Paramus, NJNPI 1386701654
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Amgen at 51.4% of the total. Reporting peaked in 2019 at $26,039 and has fallen 90.8% since, to $2,404 in 2025. Among rheumatology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,273 payments — averaging $36.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$24K
- Johnson & Johnson$6K
- Ultragenyx Pharmaceutical Inc.$4K
- AbbVie$2K
- Pfizer$1K
- GSK$1K
- plus $8K from 54 others
Across 1 payment — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$3K
What the payments were for
- Consulting fees$7,23516%
- Speaking & faculty fees$20,44844%
- Travel & lodging$7612%
- Food & beverage$17,54138%
- Education$5961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,582 in reported general payments places this provider in the 90th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 20 | $213,269 |
| Enbrel SureclickEtanercept | 28 | $204,830 |
| RinvoqUpadacitinib | 16 | $115,828 |
| SimponiGolimumab | 19 | $110,873 |
| Taltz AutoinjectorIxekizumab | 13 | $86,632 |
| TymlosAbaloparatide | 30 | $78,291 |
| OzempicSemaglutide | 57 | $59,838 |
| OtezlaApremilast | 12 | $56,694 |
| KevzaraSarilumab | 11 | $51,334 |
| EliquisApixaban | 46 | $32,925 |
| SavellaMilnacipran Hcl | 37 | $20,130 |
| ProliaDenosumab | 11 | $19,696 |
| JardianceEmpagliflozin | 17 | $14,165 |
| Hydroxychloroquine Sulfate | 352 | $13,129 |
| JanuviaSitagliptin Phosphate | 13 | $11,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella | $2,237 | $135,95853 claims |
| Johnson & JohnsonSimponi | $5,586 | $110,87319 claims |
| Radius Health, Inc.Tymlos | $203 | $78,29130 claims |
| AmgenOtezla, Prolia | $23,953 | $76,39023 claims |
| SanofiKevzara | $343 | $51,33411 claims |
| PfizerEliquis | $1,475 | $32,92546 claims |
| Boehringer IngelheimJardiance | $177 | $14,16517 claims |
| MerckJanuvia | $132 | $11,14413 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $78 | $7,805113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in Paramus
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$569K
- Jeffrey GreenbergSummit$399K
- Steven GolombekDover$318K
- Nicholas ScarpaJersey City$281K
- Adrienne HollanderVoorhees$214K
- Edward AllegraRed Bank$212K
- Nickolas TyrisSewell$201K
- Anan HaijaGalloway$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.